Table 1.

Clinical characteristics of patients used for genetic and clinical analysis

CharacteristicGenetic analysis valueClinical analysis value
Total patient number10582
Female, %54.356.1
Male, %45.743.9
Age (median)5858.5
Age range22-8728-87
Stage, %
 I19.015.9
 II5.77.3
 III27.628.1
 IV44.848.8
 NA: no information2.9
FLIPI score, %
 Low36.236.6
 Intermediate35.241.5
 High20.022.0
 NA: no information or tNHL8.6
m7 FLIPI score, %
 Low75.287.7
 High11.412.4
 NA: no information or tNHL13.3
Lymphoma type, %
 FL91.4
 Transformed lymphoma (tNHL)6.7
 NA: no information1.9
Sequenced biopsy, %
 Treatment-naive FL80.0100.0
 Treated FL*11.4
 Transformed lymphoma (tNHL)6.7
 NA: no information1.9
Treatment, %
 Rituximab containing regimen50.0
 Other treatment22.0
 Observation28.1
Best response to treatment, %
 Complete remission66.1
 Partial remission28.8
 Stable disease1.7
 Progressive disease3.4
  • * One patient with both treatment-naive and treated biopsies was only counted as treatment-naive.

  • Other treatment includes: CHOP (cyclophosphamide, hydroxydaunomycin, oncovin, prednisolone), bendamustine-ofatumumab + ofatumumab, XRT (radiation therapy), bendamustine + ofatumumab, cyclophosphamide, CVP (cyclophosphamide, vincristine, prednisolone), CVP + genitope protocol vaccine, and CHOP + XRT.

  • This excludes patients who were observed.